Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a U.S.

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...

Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

Metsera has filed for an initial public offering. The clinical-stage biopharmaceutical company submitted a registration statement to regulators on Friday, saying it intends to list under the ticker ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

The obesity market was a dominating force in 2024, with GLP-1 medications from Novo Nordisk and Eli Lilly becoming some of ...

Metsera Announces Positive Topline Phase 2a Clinical Data for its Ultra-Long Acting GLP-1 Receptor Agonist, MET-097i ...

MET-097 is under clinical development by Metsera and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication ...

Citigroup said on Friday it was expecting a rally in global equities to extend into 2025, as falling interest rates and ...

Emirati billionaire Hussain Sajwani said on Friday he expects more investments from the oil-rich Gulf into the U.S. as ...